Previously we have found an association between the combination of topical and vaginal clotrimazole treatment during pregnancy and a decrease in the prevalence of preterm births, in the population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities. Thus the objective of this secondary analysis in the expanded data set was to evaluate potential confounders and to examine the possible interaction of clotrimazole with other drugs. Medically recorded birth weight/gestational age, prevalence of preterm birth and low birthweight in newborn infants without birth defects, born to mothers with or without clotrimazole treatment during pregnancy were compared in the expanded control data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, between 1980-1996. The 17-years' data set included 38151 newborn infants. 8,1% were born to mothers who received clotrimazole treatment during pregnancy. There was an increase in the mean gestational age among the exposed as compared to the unexposed group, resulting in a significant (34-64%) reduction in the frequency of preterm births. This finding could not be explained by confounders and/or interaction with other drugs. In conclusion we may say that the protective effect of clotrimazole in preventing preterm birth was confirmed. The protective effect of topical clotrimazole during pregnancy may be attributable to the beneficial effect of clotrimazole in restoration of the abnormal colonization of the female genital organs and its known antibacterial and/or antiprotozoal effect.
|Translated title of the contribution||Reduction in the rate of premature births following clotrimazol treatment during pregnancy|
|Number of pages||10|
|Journal||Magyar Noorvosok Lapja|
|Publication status||Published - Jun 16 2006|
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology